Msh3-lowering shows HD therapeutic potential

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 17 / Springer Healthcare

Msh3-lowering shows HD therapeutic potential

Neuroscience Huntington's Disease EHDN-2022

Description

Emma Bunting shares her latest research demonstrating the slowing of somatic CAG expansion with Msh3-targeting antisense oligonucleotides in Huntington’s disease patients.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.